Part 4/8:
During the advisory committee meeting, emotions ran high as the panel discussed the potential impact of the drug on the lives of patients with DMD. Despite the strong emotional arguments in favor of the treatment, the committee ultimately could not fully endorse it due to significant concerns over the drug's efficacy.